Know Cancer

or
forgot password

Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients


N/A
N/A
N/A
Open (Enrolling)
Both
Metastatic Colorectal Cancer

Thank you

Trial Information

Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients


Inclusion Criteria:



- Histologically confirmed colorectal adenocarcinoma;

- Measurable metastatic disease according to RECIST criteria;

- Patients receiving BV plus FOLFIRI as first-line treatment;

- Written informed consent;

- Availability of blood samples for genetic analysis.-

Exclusion Criteria:

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-Free Survival

Outcome Description:

Progression free survival (PFS) is defined as time from study entry until progression of disease (according to RECIST 1.1) or death from any cause. Patients who are alive without having progressed at the end of the study will be censored at their last radiological assessment

Safety Issue:

No

Authority:

Italy: Ethics Committee

Study ID:

3108

NCT ID:

NCT01363739

Start Date:

April 2009

Completion Date:

Related Keywords:

  • Metastatic Colorectal Cancer
  • VEGF polymorphism Bevacizumab
  • Colorectal Neoplasms

Name

Location